Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Amplia Therapeutics Ltd ATX.AX: AMPLIA THERAPEUTICS REPORTS FOUR ADDITIONAL COMPLETE RESPONSES AND IMPROVED OVERALL SURVIVAL DATA IN ACCENT PANCREATIC CANCER TRIAL AMPLIA THERAPEUTICS LTD - REPORTS MEDIAN OVERALL SURVIVAL OF 11.1 MONTHS IN ACCENT TRIAL AMPLIA THERAPEUTICS LTD - REPORTS UPDATED OBJECTIVE RESPONSE RATE OF 35.9% IN ACCENT TRIAL Source text: ID:nGNX5fFw9z Further company coverage: ATX.AX
Recent news on Amplia Therapeutics
See all newsBrief: Amplia Therapeutics Signs Collaboration And Supply Agreement With Lilly
Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Brief: Amplia Therapeutics Says Warwick Tong Will Retire As Board Chairman
Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Brief: Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement